Clemens R. Scherzer, MD
Head of the Neurogenomics Lab and the Parkinson Personalized Medicine Initiative at Harvard and Brigham and Womenís Hospital
Associate Professor of Neurology at Harvard Medical School
Co-Director of the Biomarkers Program at Harvard NeuroDiscovery Center
Location: Cambridge, Massachusetts, United States
Clemens Scherzer, MD, is a physician-scientist at Harvard, Brigham and Women's Hospital, and Massachusetts General Hospital. Dr. Scherzer leads the Neurogenomics Lab and Parkinson Personalized Medicine Program, and co-founded and co-directs the Biomarkers Program of the Harvard NeuroDiscovery Center. He is associate professor of neurology at Harvard Medical School.
Dr. Scherzer uses genetics and big data to develop a new, proactive and personalized medicine for Parkinson's disease. His interdisciplinary lab includes computer scientists, biologists and clinicians. The lab's goal is to match drugs and tests to a patient's disease driver based on a search of his entire biology. This Parkinson's discovery engine is powered by massive genome, biology and health data being generated from the Harvard Biomarkers Study, today with more than 2,300 participants, one of the largest longitudinal biobanks for Parkinson's in the world. To understand how the human genome encodes human brain cells in health and disease, Dr. Scherzer is leading the BRAINCODE project with funding from the National Institutes of Health and the Department of Defense. This initiative is establishing a BRAIN Cell encyclOpeDia of all transcribed Elements in specific types of human brain cells using ultra-deep, cell-type specific, total RNA sequencing.
Dr. Scherzer completed his neurology residency at Emory University and received the Dr. Paul Beeson and the George C. Cotzias Memorial Awards. He serves on the steering committee of the NIH Parkinson's Disease Biomarkers Program, the vision setting panel of the Department of Defense Parkinson Program, and the scientific advisory board of the American Parkinson Disease Foundation. He serves on the editorial boards of Neurogenetics and Biomarkers in Medicine.
- Identification of Genetic Signatures in the Blood as Biomarkers for Parkinson's Disease (2016)
- GBA Meta-analysis Initiative: Charting a Path to Success for Clinical Trials in Patients with GBA-PD (2016)
- Contrasting Pathological Versus Normal Alpha-synuclein Assemblies (2014)
- Genetic Predictors of Prognosis: GBA and SNCA Meta-Analysis Project (2014)
- Probing Nurr1 Expression in Parkinsonís Disease (2014)
- From Genetic Risk Toward Genetic Prognosis (2013)
- Peripheral Blood-based Transcript Biomarkers for Prediction of Parkinson Disease in LRRK2 Mutation Carriers (2013)
- Alpha-Synuclein-Expression-Lowering Therapeutics: Initial Pre-Clinical Development (2013)
- Evaluation of PD-linked Transcripts in PPMI (2012)
- Alpha-synuclein Expression Lowering therapeutics: Hit Confirmation (2011)
- Unlimited Discovery of Non-Coding, Regulatory RNAs and Aberrant Splicing in Parkinson's (2011)
- Development and Initial Characterization of an Enzyme-linked Immunosorbent Assay for the Candidate PD Risk Marker ST13 (2007)
- Simple Blood Tests for Parkinson's Disease Derived from Genome-wide Expression Changes (2004)
- Gene Expression in Parkinson's Disease (2004)
- Simple Blood Tests for Parkinson's Disease Derived from Genome-wide Expression Changes (2002)